Partner With Us
Bring us your validated target. We programme the multispecific immune response — from functional screen to clinical candidate.
CB-101 is designed for patients with heterogeneous antigen expression — the population where OR-gate architecture provides the greatest clinical advantage.
What we bring
- OR-gated multispecific platform, functionally screened across 20+ tumour targets
- CB-101: myeloma trispecific, IND-enabling stage
- CB-102: solid tumours, in vivo PoC complete
- Prof. Nikhil Munshi (Dana-Farber) as lead myeloma KOL
What we're looking for
- Validated oncology or autoimmune targets, defined patient population
- Phase 1 infrastructure, CRO relationships, or KOL network
- Co-development, licensing, or option-to-license — flexible on structure
- Portfolio-builders, not single-asset positions
Get in touch
Enquiries are reviewed by the Coding Bio business development team.
Your data is processed in accordance with applicable data protection law. We do not share your information with third parties.